TNGX stock hits record high on inking collaboration deal with ERAS
The article reports that TNGX stock has reached a record high following the announcement of a new collaboration deal with ERAS. This partnership is likely perceived positively by investors, driving the significant increase in TNGX's stock value.
S&P 500 Futures Decline in Premarket Trading; Valmont Industries, Loews Lag
S&P 500 futures are declining in premarket trading, with specific companies like Valmont Industries and Loews lagging. Conversely, Humana Inc. (HUM) and Brookfield Wealth Solutions Ltd. (BNT) are showing significant gains, up 9.8% and 9.7% respectively, as the U.S. stock markets approach their open. This article provides an early look at market movements before trading begins.
Hospital for Special Surgery surgeon takes top tech role at Zimmer Biomet
Zimmer Biomet (NYSE: ZBH) has appointed Dr. Jonathan M. Vigdorchik as its Chief Science, Technology and Medical Affairs Officer, effective April 14, 2026. Dr. Vigdorchik, an experienced orthopedic surgeon from Hospital for Special Surgery, will oversee the company's global technology portfolio, including AI, robotics, smart implants, and data, along with Medical Education and the Global Advisory Board. This appointment underscores Zimmer Biomet's continued focus on advancing innovation in musculoskeletal care, particularly in robotics and AI.
Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
Zimmer Biomet Holdings, Inc. has announced the appointment of Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer, effective April 14th. In this role, Dr. Vigdorchik, an experienced orthopedic surgeon from the Hospital for Special Surgery, will oversee the company's global technology portfolio, including AI, robotics, smart implants, and data, as well as its Medical Education strategy. This appointment aims to enhance Zimmer Biomet's clinical engagement, innovation roadmap, and external scientific leadership in musculoskeletal care.
See the list of Minnesota’s largest employers and Target’s new ranking
Minnesota's 16 largest employers saw a 1% reduction in their workforce over the last year, with Mayo Clinic retaining its position as the largest employer. Target Corp. dropped from third to fourth place after cutting 3,000 jobs, while the state and federal governments reported significant employment increases. Financial services companies, U.S. Bancorp and Wells Fargo, experienced the steepest job reductions.
BD Launches HemoSphere Stream Module for Continuous Blood Pressure Monitoring
BD has launched its HemoSphere Stream™ Module, a new noninvasive technology for continuous blood pressure monitoring. This module, used with the VitaWave™ Plus Finger Cuff, provides real-time arterial waveform data, improving patient safety by allowing earlier detection of hemodynamic changes. The innovation aims to enhance care quality and solidify BD's leadership in medical technology.
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatments, announced its management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026. The company is developing novel medicines to normalize CFTR protein function, specifically targeting the F508del genetic mutation. Sionna aims to improve clinical outcomes and quality of life for CF patients through its pipeline of NBD1 stabilizers and complementary CFTR modulators.
Blood pressure checks every 3–5 minutes leave gaps; BD offers a live view
BD (Becton, Dickinson and Company) has launched the HemoSphere Stream™ Module, a new device that provides continuous, noninvasive, beat-to-beat arterial waveform data to compatible bedside monitors. This system, used with the VitaWave™ Plus Finger Cuff, aims to eliminate blind spots from intermittent blood pressure checks, typically taken every 3-5 minutes, and enhance patient safety by allowing for earlier detection and treatment of hemodynamic changes. The technology has been validated against arterial line measurements and supports APSF recommendations for continuous noninvasive hemodynamic monitoring, particularly important during and after surgery.
Rathbones Group PLC Sells 12,766 Shares of Medtronic PLC $MDT
Rathbones Group PLC reduced its stake in Medtronic PLC by 19.5% in the fourth quarter, selling 12,766 shares but still holding 52,746 shares valued at approximately $5.07 million. This comes as Medtronic modestly exceeded Q4 expectations and provided optimistic FY2026 guidance, despite a significant insider share sale by EVP Harry Skip Kiil. The company's stock has an average "Moderate Buy" rating from analysts, with a consensus price target of $109.85.
Thermo Fisher Scientific appoints Somya Sugandha as VP HR, APMEA
Somya Sugandha has been appointed as Vice President, Human Resources for the APMEA region at Thermo Fisher Scientific. With over 25 years of experience from companies like Alstom, General Electric, and GE Vernova, Sugandha will be responsible for aligning people strategy, driving talent strategy, and enhancing organizational effectiveness. Her role will focus on fostering growth and cultural transformation within the diverse APMEA region.
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook
Biogen has expanded its neurology and rare disease portfolio by acquiring Apellis Pharmaceuticals and securing FDA approval for a high-dose regimen of SPINRAZA for spinal muscular atrophy. These strategic moves aim to diversify Biogen's pipeline and revenue streams, particularly within the growing market for rare disease and specialty medicines. Investors will be closely watching the integration of Apellis' assets and the adoption rate of the new SPINRAZA regimen to assess their impact on the company's financial performance.
Citi Downgrades Insulet Corporation (PODD) to Neutral
Citi analyst Joanna Wuensch downgraded Insulet Corporation (NASDAQ: PODD) to Neutral. The article is premium-only content, requiring a subscription to StreetInsider.com to view the full details of the downgrade.
Outset Medical adds former Stryker leader as new EVP of commercial
Outset Medical has appointed Derick Elliott, formerly of Stryker and Cardinal Health, as its new Executive Vice President of Commercial. Effective immediately, Elliott will oversee the company's commercial organizations supporting acute, post-acute, and home healthcare providers. His extensive experience in medtech sales and marketing, including his previous role as CCO at SpendMed, aligns with Outset Medical's strategy for its portable hemodialysis system, Tablo.
AbbVie Inc. $ABBV Shares Sold by Sound Income Strategies LLC
Sound Income Strategies LLC has reduced its stake in AbbVie Inc. (ABBV) by 8.3%, selling 8,649 shares, leaving them with 95,984 shares valued at $20.57 million. This comes as AbbVie lowered its Q1 and full-year 2026 earnings outlook due to a $744 million R&D charge, contributing to recent share weakness. Insider selling has also been reported, with two executives selling significant numbers of shares.
Stryker’s global manufacturing network now “fully operational” following cyberattack
Stryker has announced that its global manufacturing network is fully operational again after a cyberattack disrupted its operations. The company stated that production is rapidly moving towards peak capacity with strong product supply across most lines, assuring customers and partners that patient care remains the highest priority. Stryker also clarified that the incident was not ransomware, was contained, and did not compromise product safety or customer data, though some personalized implant cases were rescheduled due to shipping delays.
Bernstein Adjusts Price Target on UnitedHealth Group to $411 From $405, Maintains Outperform Rating
Bernstein has raised its price target for UnitedHealth Group (UNH) to $411 from $405, while reiterating an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm on the integrated healthcare company.
Diabetes device recall surge reveals a worrying information gap
The article highlights a significant increase in diabetes device recalls, particularly for continuous glucose monitors (CGM) and insulin pumps, indicating a growing problem in the medical device industry. This surge in recalls suggests a concerning information gap related to the safety and efficacy of these essential medical devices. The report mentions specific Class I and Class II recalls in 2025 involving major companies like Abbott Laboratories, Tandem Diabetes Care, Dexcom, Medtronic, and Insulet Corp.
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
Alloy Therapeutics has announced a multi-target collaboration and license agreement with Biogen for the use of Alloy’s AntiClastic™ ASO Platform. This collaboration aims to accelerate the development of innovative oligonucleotide therapeutics, building on previous work between the two companies. Alloy will receive an upfront payment and is eligible for milestone payments and royalties on products developed using the platform, which is designed to overcome potency and therapeutic index challenges in antisense therapeutics.
Evaluating Danaher (DHR) After Mixed Recent Returns And Conflicting Undervaluation Signals
Danaher (DHR) is currently facing mixed investor sentiment due to a year of positive returns contrasted with recent declines over the last three months and month, alongside a 4.5% uptick in the past week. Despite having a projected fair value of $264.91, suggesting it's 27.5% undervalued, other analyses indicate a 13.2% undervaluation but with an expensive P/E ratio. The article advises investors to further analyze the company's prospects given these conflicting signals and potential risks.
CMS Medicare Rate Decision Reframes UnitedHealth Group Valuation And Risk Profile
The CMS has finalized a 2.48% rate increase for 2027 Medicare Advantage and Part D payments, which is higher than initially expected and provides clarity for UnitedHealth Group, a major Medicare Advantage operator. This decision offers a more supportive baseline for Medicare Advantage profitability, despite ongoing questions about medical costs and competitive pressures. While the company's shares are considered undervalued by Simply Wall St, a flagged risk is UnitedHealth Group's high debt level.
Caledonia Mining, 88 Energy, MobilityOne, MedPal AI, Coro Energy - Small Cap Snapshot
This snapshot provides updates on several small-cap companies. Caledonia Mining's deep drilling at Blanket Mine shows promising results, while 88 Energy acquired new 3D seismic data for its Alaskan leases to inform future exploration. MobilityOne’s joint venture with Super Apps has been approved by shareholders, MedPal AI reported record dispensing volumes, and Coro Energy signed a solar leasing deal in Vietnam.
Daytona Street Capital LLC Invests $749,000 in Alpha Tau Medical Ltd. $DRTS
Daytona Street Capital LLC initiated a new position in Alpha Tau Medical Ltd. (NASDAQ:DRTS) during the fourth quarter, purchasing 151,227 shares valued at $749,000. This investment represents approximately 0.18% of Daytona Street Capital's portfolio. Other institutional investors like Apella Capital LLC, Levin Capital Strategies L.P., Mariner LLC, Millennium Management LLC, and Bank of America Corp DE also adjusted their holdings in Alpha Tau Medical. The company, which develops targeted alpha-radiation therapy for solid tumors, has a market cap of $579.3 million, a "Hold" consensus analyst rating, and an average price target of $8.67.
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High - What's Next?
Day One Biopharmaceuticals (NASDAQ:DAWN) recently hit a new 52-week high of $21.47, trading with heavy volume. Despite this, analyst consensus is a "Hold" with an average target price of $23.29, and several firms have reduced their price objectives. The company reported a quarterly EPS miss but a revenue beat, and institutional ownership remains high while insiders have recently sold shares.
Daytona Street Capital LLC Takes Position in Cencora, Inc. $COR
Daytona Street Capital LLC has acquired 40,000 shares of Cencora, Inc. (NYSE:COR) during the fourth quarter, making it their largest holding at roughly 9.0% of their investment portfolio. This move values their stake at approximately $13.51 million. Cencora recently reported earnings per share that beat analyst expectations, though revenue slightly missed estimates, and maintains a "Moderate Buy" consensus rating among analysts.
AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug
AstraZeneca's immunotherapy drug, Imfinzi, has shown significant success in a Phase III trial for unresectable liver cancer, a difficult-to-treat condition. This breakthrough positions Imfinzi to potentially achieve "super-blockbuster" status with projected annual sales of $11 billion by 2030, according to Citi analysts. The drug is already approved for other cancers, and further trial results for bladder and esophageal cancers are anticipated later this year, reinforcing its importance to AstraZeneca's growth.
3 Dividend Stocks for April 2026
This article identifies three dividend stocks—Air Products and Chemicals (APD), Fidelity National Information Services (FIS), and Roche Holding (RHHBY)—for April 2026. These companies, all possessing Morningstar Economic Moat Ratings, recently increased their dividends, indicating strong financial health and commitment to shareholder returns. While not all are currently undervalued, they are presented as solid options for income investors.
Daytona Street Capital LLC Makes New $1.36 Million Investment in Bristol Myers Squibb Company $BMY
Daytona Street Capital LLC has initiated a new position in Bristol Myers Squibb Company (NYSE:BMY), purchasing 25,247 shares valued at approximately $1.36 million during the fourth quarter. This move comes as other institutional investors have also adjusted their holdings in the biopharmaceutical company. Bristol Myers Squibb recently reported mixed quarterly results, with EPS missing estimates but revenue exceeding expectations, and declared a quarterly dividend of $0.63.
Centene Corp. stock: Why it's drawing investor attention amid healthcare shifts
Centene Corp. is gaining investor attention due to a 4% stock increase following a rise in Medicare Advantage rates for 2027, signaling brighter prospects for the managed care giant. The article details Centene's business model focused on government-funded healthcare programs like Medicaid and Medicare, its competitive advantages in a fragmented market, and risks including regulatory changes and competition. Analysts hold a cautious "Hold" rating with potential upside, making it a defensive play for long-term investors.
Daytona Street Capital LLC Invests $2.69 Million in CVS Health Corporation $CVS
Daytona Street Capital LLC has acquired a new position of 33,888 shares in CVS Health Corporation, valued at approximately $2.69 million, making it their 16th largest holding. This investment comes as CVS reported strong Q4 results, exceeding EPS and revenue estimates, and announced a quarterly dividend of $0.665. Analysts maintain a "Moderate Buy" rating for CVS with an average target price of $94.95.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts
Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received a "Moderate Buy" consensus rating from eight analysts, with an average one-year price target of $7.60. Despite missing EPS estimates slightly, the company exceeded revenue expectations. Institutional investors, including Vanguard and State Street, have increased their stakes, with institutions now owning approximately 47.39% of the company.
Fulton Breakefield Broenniman LLC Has $14.87 Million Stock Position in UnitedHealth Group Incorporated $UNH
Fulton Breakefield Broenniman LLC reduced its stake in UnitedHealth Group (UNH) by 8.3% in Q4, now holding 45,041 shares valued at $14.87 million. The healthcare conglomerate is experiencing positive sentiment due to a larger-than-expected Medicare Advantage payment increase for 2027, boosting its revenue outlook. Analysts maintain a "Moderate Buy" rating with a target price of $363.38, while the company anticipates Q1 earnings on April 21st.
Fulton Breakefield Broenniman LLC Acquires 14,641 Shares of Stryker Corporation $SYK
Fulton Breakefield Broenniman LLC increased its stake in Stryker Corporation by 41.3%, purchasing 14,641 additional shares and bringing its total holdings to 50,123 shares valued at $17.617 million. This makes Stryker its 25th-largest position. Despite a director selling 250,000 shares for $90.73 million, institutional investors still own 77.09% of the company.
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $3.52
Truist Financial has reiterated its Buy rating on AbCellera Biologics (ABCL.US), setting a target price of $3.52. This indicates a positive outlook from the financial firm regarding the company's stock performance. Investors will likely consider this analyst rating and price target when evaluating their position in AbCellera Biologics.
JPMorgan Chase & Co. Sells 271,731 Shares of Enhabit, Inc. $EHAB
JPMorgan Chase & Co. decreased its stake in Enhabit, Inc. (NYSE:EHAB) by 48.2% in the third quarter, selling 271,731 shares and retaining 291,823 shares valued at $2.34 million. Enhabit reported Q3 EPS of $0.14 and revenue of $270.4 million, with a current market cap of $708.81 million. Analyst consensus rates Enhabit as a "Hold" with an average target price of $13.57.
Country Trust Bank Increases Holdings in UnitedHealth Group Incorporated $UNH
Country Trust Bank increased its stake in UnitedHealth Group (UNH) by 14.7% in Q4, acquiring an additional 18,484 shares, making UNH its 28th largest position valued at $47.5 million. The company reported solid Q4 earnings, slightly beating expectations, and provided positive FY2026 EPS guidance. Upcoming Q1 results on April 21st and a favorable CMS decision for Medicare Advantage payments are key near-term catalysts for UNH amidst recent stock weakness.
Fulton Breakefield Broenniman LLC Reduces Stock Holdings in Danaher Corporation $DHR
Fulton Breakefield Broenniman LLC significantly reduced its stake in Danaher Corporation by 27.9% in Q4, selling 18,647 shares and retaining 48,301 shares valued at $11.06 million. The article also notes Danaher's strong Q4 earnings, surpassing analyst estimates, and a recent dividend increase from $0.32 to $0.40 per share, yielding 0.8%. Analysts maintain a "Moderate Buy" rating for Danaher, with an average price target of $253.79.
COO SEC Filings - Cooper 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for CooperCompanies (COO) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. Stock Titan enhances these filings with AI-powered summaries, real-time updates, and sentiment analysis for better investor understanding. Recent filings highlight insider purchases by executives and report Q3 2025 results with details on gross margin, acquisitions, and a disclosed material weakness in IT general controls.
Ulta Beauty sees GLP-1 trend lift demand for hair and skincare
Ulta Beauty is experiencing increased demand for hair and skincare products due to the rising use of GLP-1 weight-loss drugs. CEO Kecia Steelman noted that rapid weight loss from these drugs leads to concerns like hair loss and skin moisture, driving shoppers to seek specific beauty products. This trend, with GLP-1 users expected to account for 10% of the U.S. population in 2025, is impacting Ulta's sales, particularly in its skincare, wellness, and hair care categories, which contribute significantly to its $12.39 billion annual revenue.
Despite Recent Gains, Altimmune Insiders Are Still Down US$29k
This article states that despite some recent positive share price movement, Altimmune insiders are still collectively down US$29k on their investments over the last year. This is primarily due to a significant share price decline, meaning recent share purchases by insiders have not yet compensated for previous losses.
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages
Coherus Oncology, Inc. (NASDAQ:CHRS) has received an average "Hold" recommendation from five research firms, with analysts providing one sell, one hold, and three buy ratings. The average 1-year target price for the stock is $5.5125. Major institutional investors and hedge funds hold 72.82% of the company's stock, and Coherus Oncology recently reported Q4 earnings per share of ($0.34), missing analyst expectations.
Cytokinetics to Participate in Annual Healthcare Conference
Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. Management will present in a fireside chat to discuss updates on its pipeline, including its approved drug MYQORZO®, and engage with the healthcare investment community. A webcast of the presentation will be available on the company’s website for 90 days.
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock that they have an opportunity to lead a securities fraud lawsuit. The lawsuit alleges that Corcept misrepresented the strength of its clinical trials for relacorilant and its chances of FDA approval. Investors who purchased Corcept stock between October 31, 2024, and December 30, 2025, have until April 21, 2026, to move the court to be appointed as lead plaintiff.
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition
TD Cowen downgraded Soleno Therapeutics (NASDAQ:SLNO) from Buy to Hold and lowered its price target to $53.00 from $85.00 after Neurocrine Biosciences announced its acquisition of Soleno Therapeutics for $53 per share, totaling approximately $2.9 billion. This acquisition price represents a 51% premium over the 30-day volume-weighted average price. Other firms like Stifel and Oppenheimer also downgraded Soleno, reflecting the market's expectation for the stock to trade near the acquisition price until the deal closes.
Evotec nominates Dieter Weinand as supervisory board chairman
Evotec SE has announced the nomination of Dieter Weinand as the new chairman of its supervisory board, succeeding Prof. Dr. Iris Löw-Friedrich. Weinand brings over 30 years of experience in the pharmaceutical industry, having held leadership roles at companies like Bayer AG, Pfizer, Bristol Myers Squibb, and Sanofi. His election is proposed for the company's annual general meeting on June 11, 2026, and he plans to reduce his current board positions to focus on Evotec's transformation.
Celldex Therapeutics Closes $345M Public Stock Offering
Celldex Therapeutics, a clinical-stage biotech company, has closed a $345 million public stock offering, including the full exercise of the underwriters' option to purchase additional shares. The company sold nearly 12 million shares at $29 each, resulting in gross proceeds of approximately $345 million. Celldex plans to use these funds to advance its pipeline of antibody-based treatments for severe inflammatory, allergic, and autoimmune diseases, demonstrating investor confidence in its immune-based therapies.
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals
Regeneron Pharmaceuticals (REGN) is under renewed focus after the FDA approved extended dosing intervals for EYLEA HD, impacting its valuation. The stock currently trades at $763.04, with a 1-year return of 33.94%, and a most popular valuation narrative suggesting it's 12.7% undervalued with a fair value of $873.78. This valuation is supported by its broad pipeline, including immunology, oncology, genetic medicines, and obesity treatments, though competitive pressures and R&D costs present risks.
Incyte Names Cagnoni President, Announces Leadership Changes
Incyte (Nasdaq: INCY) has announced significant executive leadership changes, appointing Pablo J. Cagnoni, M.D., as President and Global Head of R&D to lead enterprise-wide strategy and operations. Steven Stein, M.D., is now EVP, Chief Medical Officer, and Head of Late-Stage Development, while Mohamed Issa, Pharm.D., expands his role to EVP and Head of U.S. Commercial, unifying oncology and immunology teams. These changes aim to support Incyte's long-term growth strategy and upcoming product launches.
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals
Regeneron Pharmaceuticals (REGN) is under valuation scrutiny after the FDA approved extended dosing for EYLEA HD, easing treatment schedules. Despite a 34% one-year total shareholder return, the stock's year-to-date performance is slightly negative. Simply Wall St's analysis suggests REGN is modestly undervalued at $763.04, with a fair value pegged at $873.78, though its P/E ratio is higher than the US Biotech average.
Allspring Global Investments Holdings LLC Buys 8,381 Shares of Molina Healthcare, Inc $MOH
Allspring Global Investments Holdings LLC significantly increased its stake in Molina Healthcare, Inc. (NYSE:MOH) by 27.4% during the fourth quarter, acquiring an additional 8,381 shares, bringing its total holdings to 38,913 shares valued at approximately $6.94 million. This move comes despite Molina Healthcare reporting a substantial earnings per share miss of ($2.75) against an expected $0.43, though revenue beat estimates at $11.38 billion. The company has a consensus "Hold" rating from analysts with an average price target of $169.21, and institutional investors currently own about 98.50% of its stock.
Aaron Wealth Advisors LLC Grows Stock Position in Astrazeneca Plc $AZN
Aaron Wealth Advisors LLC increased its stake in AstraZeneca Plc by 31.9% in the fourth quarter, now holding 27,984 shares valued at $2.573 million. AstraZeneca's stock opened at $202.85, boasts a market capitalization of $314.6 billion, and has a P/E ratio of 30.97. The company recently paid a dividend of $1.595, and analysts currently give it a "Moderate Buy" rating with an average target price of $95.75.
